April 8, 2024
MSD’s PD-1 inhibitor Keytruda (pembrolizumab) remained the best-selling medicine in the Japan pharma market in March, extending its winning streak to the sixth straight month, according to a monthly snapshot report released by Encise. Keytruda brought in sales of 12.7...read more